Pfizer Reports Lung Cancer Development In Some Exubera Users
Primary lung malignancies have developed in several patients taking Pfizer's inhaled insulin Exubera, which it stopped marketing last fall, but the relationship between the adverse event and the drug remains unclear
You may also be interested in...
Firm now faces the commercial gauntlet of establishing an inhaled insulin in the crowded diabetes market.
FDA advisory committee review of MannKind’s inhaled insulin revisits safety issues that troubled Pfizer’s first-of-its-kind product, including a potential lung cancer risk and declines in pulmonary function.
Pfizer's decision to terminate its Exubera program - the first inhaled insulin product to hit the market - could provide an opportunity for other drug makers looking to step into the market, especially those prepared to address obstacles illuminated by Pfizer